Sodium Monofluorophosphate is the salt form of its parent API, engineered to achieve a target aqueous solubility and dissolution profile that ensures consistent oral bioavailability across the patient population. The stoichiometry of API to counter-ion, defined in the salt’s molecular formula, determines the dose equivalent and the appropriate molecular weight correction applied when converting the PDE value to a cleaning validation maximum allowable carryover expressed in mass of salt per unit equipment surface area or per unit rinse volume.
The pharmacologically-based OEL approach is used for Sodium Monofluorophosphate when its receptor-mediated pharmacodynamic activity in humans produces the most sensitive adverse effect at doses below the NOAEL from general organ toxicity studies. The pharmacodynamic NOAEL established from clinical pharmacology studies—typically from the lowest dose producing a measurable but non-adverse pharmacological effect in healthy volunteers—is divided by t
